Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
about
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.BEZ235: When Promising Science Meets Clinical RealityEfficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphomaOutcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Targeting of B-cell receptor signalling in B-cell malignancies.Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.From identification of the BTK kinase to effective management of leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.The landscape of new drugs in lymphomam-TOR inhibitors and their potential role in haematological malignancies.Novel agents in mantle cell lymphoma.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma.Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.The role of B cell antigen receptors in mantle cell lymphoma.Safety and efficacy of ibrutinib in a patient with severe renal impairment.Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study."Neurological complications of new chemotherapy agents".Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.Role of Bruton's tyrosine kinase in B cells and malignancies.
P2860
Q28070090-05EB77B4-4645-4852-9FCD-1606DABD5487Q30248407-C323234E-7398-4C92-A328-32D693DC6792Q33761496-92CEE3F1-549C-46CE-BF52-A5C6EBAC45A2Q36384588-0751E163-D1EB-47E0-901A-7C9FEE56C0F8Q37242369-E31F5B7F-2B34-4C83-A072-600438596861Q37544340-04720AEC-2BD8-454B-BD2C-AF0159D12189Q38612385-1AF6497E-56E0-462C-8469-BA1CC3C69CF1Q38644259-D7E1E60F-C712-4622-AD04-23C97F9719F7Q38656503-6E4FEC5B-7B4F-4688-8462-9E1DBB5D37ACQ38665207-2A8B3824-71ED-4FB1-A890-7240AE119182Q38691282-08188BE0-3CF3-4EAB-889B-24B59585B461Q38719429-FF19974F-4C8B-43C3-8971-32A3A4365B81Q38744922-1BAB3ADB-7E93-4730-B263-401C22358702Q38763829-E88684D6-B7ED-401E-9A39-F95C77F84DCDQ38817591-3A56F2D8-2286-4F59-8E9B-DBA2479D07C1Q38819164-36715023-487E-40E6-B08D-D2CAC2511591Q38896793-45EBFFE4-2ADA-4ECA-8F6C-E64D7698B008Q38969861-8405A820-E614-4CA2-8F68-172695D81936Q39045701-8D8F3053-368C-4DD4-B4FF-EAE2F68A2533Q39061630-2C3C92DB-7649-4FC8-96F3-4D974F44CB8DQ39113506-A2D3C5C5-DC0F-40B4-A47D-6246FE3F3D97Q39290199-1B6E1337-2B01-49F3-8DA1-B66AA43B0ABAQ39325783-C9ED8BF1-695E-4CD4-AAC2-858A48DF5539Q39383524-20056802-FDF9-4740-B074-418D6053FA63Q41374031-59EF932D-5BF3-4C5B-AEA5-08CC1A34A141Q41817685-022D6E20-6340-453A-B41D-D86CD75E4F8DQ42363894-63CF0E60-E007-4481-9C53-43FC7ED5E6DEQ42368314-0D1346A0-6C34-46F6-9268-7E9C1F2C1E5AQ42682371-88797CE3-4E2F-4E2B-AD04-B4DD679C0223Q42699972-4B47B3C7-6D76-4776-9F04-9BACDBAAFBC4Q43296855-6EE9D679-D463-459D-8B97-AE610296105AQ45050435-A272955C-9C2C-4905-A6B2-281F41901B3CQ45069581-1C9EFD0E-F082-4A91-BFDD-E243B2FF8F50Q47387312-110AE820-6F8E-4090-A897-6DEE42DEE807Q47699487-C91C84EC-A7D5-4B25-BA9B-C45CA684F4C3Q48238170-35EAA04B-293E-418E-9A53-58AB6E992A36Q48273854-DF8C5DBA-F848-4ABA-8356-F2300A851C72Q48669191-4801567B-2D21-4834-BD9A-2F2BC64EB30BQ49731233-44A4ABBB-F3D3-45D0-A390-C7D29AACAD5AQ49888075-A37C3D82-820C-4595-A430-EC461CCA3295
P2860
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ibrutinib versus temsirolimus ...... ed, open-label, phase 3 study.
@en
type
label
Ibrutinib versus temsirolimus ...... ed, open-label, phase 3 study.
@en
prefLabel
Ibrutinib versus temsirolimus ...... ed, open-label, phase 3 study.
@en
P2093
P50
P1433
P1476
Ibrutinib versus temsirolimus ...... ed, open-label, phase 3 study.
@en
P2093
Aleksandra Rizo
Chiara Rusconi
Christopher Enny
Dolores Caballero
Fritz Offner
Georg Hess
Isabelle Bence-Bruckler
Jenna D Goldberg
Jessica Vermeulen
John Bothos
P304
P356
10.1016/S0140-6736(15)00667-4
P407
P577
2015-12-04T00:00:00Z